Click Therapeutics' digital therapeutic (DTx) CT-132 has been approved by the FDA, becoming the first treatment of its type in the US for preventing attacks in people with episodic migraine.

The Karyopharm Therapeutics Inc.-Bond has a maturity date of 10/15/2025 and offers a coupon of 3.0000%. The payment of the coupon will take place 2,0 times per biannual on the 15.04.. The ...